Reperfusion strategies in the emergency treatment of ST-segment elevation myocardial infarction

被引:19
作者
Peacock, W. Frank [1 ]
Hollander, Judd E.
Smalling, Richard W.
Bresler, Michael J.
机构
[1] Cleveland Clin, Dept Emergency Med, Cleveland, OH 44195 USA
[2] Hosp Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA
[3] Univ Texas, Sch Med, Div Cardiovasc Med, Houston, TX 77225 USA
[4] Mem Hermann Heart & Vasc Inst, Houston, TX 77225 USA
[5] Stanford Univ, Sch Med, Dept Surg, Div Emergency Med, Stanford, CA 94305 USA
关键词
D O I
10.1016/j.ajem.2006.07.013
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Prompt restoration of blood flow is the primary treatment goal in ST-segment elevation myocardial infarction to optimize clinical outcomes. The ED plays a critical role in rapid triage, diagnosis, and management of ST-elevation myocardial infarction, and in the decision about which of the 2 recommended reperfusion options, that is, pharmacologic and mechanical (catheter-based) strategies, to undertake. Guidelines recommend percutaneous coronary intervention (PCI) if the medical contact-to-balloon time can be kept under 90 minutes, and timely administration of fibrinolytics if greater than 90 minutes. Most US hospitals do not have PCI facilities, which means the decision becomes whether to treat with a fibrinolytic agent, transfer, or both, followed by PCI if needed. Whichever reperfusion approach is used, successful treatment depends on the ED having an integrated and efficient protocol that is followed with haste. Protocols should be regularly reviewed to accommodate changes in clinical practice arising from ongoing clinical trials. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:353 / 366
页数:14
相关论文
共 81 条
[1]   Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide, monotherapy in acute Myocardial Infarction (ADVANCE MI) trial [J].
Adgey, J ;
Ardissino, D ;
Armstrong, P ;
Berger, P ;
Betriu, A ;
Beyar, R ;
Bode, C ;
Braunwald, E ;
Brindis, R ;
Brogan, G ;
Buller, C ;
Califf, R ;
Casterella, P ;
Gibler, WB ;
Giugliano, R ;
Goldstein, P ;
Granger, C ;
Guetta, V ;
Harrington, R ;
Herrmann, H ;
Hochman, J ;
Hoekstra, J ;
Kleiman, N ;
Labinaz, M ;
Langer, A ;
Montalescot, G ;
Ohman, EM ;
O'Neill, W ;
Pollack, C ;
Roe, M ;
Satler, L ;
Schweiger, M ;
Simoons, M ;
Steg, G ;
Tanguay, JF ;
Van de Werf, F ;
Wallentin, L ;
Zeymer, U .
AMERICAN HEART JOURNAL, 2005, 150 (01) :116-122
[2]   Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Alto, P ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
Van de Werf, F ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :959-969
[3]  
[Anonymous], 1988, LANCET, V2, P349
[4]  
[Anonymous], 1986, LANCET, V1, P397
[5]  
Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014
[6]   Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction [J].
Antman, EM ;
Morrow, DA ;
McCabe, CH ;
Murphy, SA ;
Ruda, M ;
Sadowski, Z ;
Budaj, A ;
López-Sendón, JL ;
Guneri, S ;
Jiang, F ;
White, HD ;
Fox, KAA ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (14) :1477-1488
[7]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[8]   A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents [J].
Babapulle, MN ;
Joseph, L ;
Bélisle, P ;
Brophy, JM ;
Eisenberg, MJ .
LANCET, 2004, 364 (9434) :583-591
[9]   Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (Recombinant plasminogen activator) and front-loaded, accelerated alteplase (Recombinant tissue plasminogen activator) in patients with acute myocardial infarction [J].
Bode, C ;
Smalling, RW ;
Berg, G ;
Burnett, C ;
Lorch, G ;
Kalbfleisch, JM ;
Chernoff, R ;
Christie, LG ;
Feldman, RL ;
Seals, AA ;
Weaver, WD .
CIRCULATION, 1996, 94 (05) :891-898
[10]   Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour [J].
Boersma, E ;
Maas, ACP ;
Deckers, JW ;
Simoons, ML .
LANCET, 1996, 348 (9030) :771-775